AstraZeneca PLC (AZN)vsMirum Pharmaceuticals Inc (MIRM)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
MIRM
Mirum Pharmaceuticals Inc
$107.16
+4.11%
HEALTHCARE · Cap: $6.28B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 11494% more annual revenue ($60.44B vs $521.31M). AZN leads profitability with a 17.2% profit margin vs -4.5%. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
MIRM
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+47.2%
Fair Value
$189.03
Current Price
$107.16
$81.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Revenue surging 49.8% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Trading at 17.7x book value
0.0% earnings growth
ROE of -8.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : MIRM
The strongest argument for MIRM centers on Revenue Growth. Revenue growth of 49.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : MIRM
The primary concerns for MIRM are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while MIRM is a hypergrowth play — different risk/reward profiles.
MIRM carries more volatility with a beta of 0.52 — expect wider price swings.
MIRM is growing revenue faster at 49.8% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 30/100), backed by strong 17.2% margins and 12.5% revenue growth. MIRM offers better value entry with a 47.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Mirum Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?